Smartphone Apps for Preventing Adolescent Health Problems Among Health Care Professionals: Systematic Search and Quality Assessment.

JMIR Mhealth UhealthSep 11, 2026 (epub)
Clinical ResearchPediatricsPreventive Medicine / Public Health

Elodie Million, Marijn Kuijper, Carole Bautista et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated smartphone apps aimed at helping healthcare professionals identify at-risk adolescents across various preventive health areas. Out of 976 apps identified, only 9 were retained, with 7 meeting quality criteria, primarily focusing on mental and sexual health. The mean Mobile App Rating Scale (MARS-F) score ranged from 2.5/5 to 3.8/5.

Key findings

  • Only 7 out of 976 apps met the quality criteria for adolescent health prevention.
  • The mean MARS-F interrater score ranged from 2.5/5 to 3.8/5.
  • Three out of eight relevant prevention areas were addressed by the validated apps.

Why it matters

Understanding the limited availability and quality of digital tools for adolescent health prevention is crucial for healthcare professionals. This knowledge can guide their selection of effective resources to better support at-risk youth.

Source

PubMed · PMID 42727054

Published in JMIR Mhealth Uhealth. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.